How to appeal a Premera Blue Cross chronic wound care denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Premera Blue Cross-specific note: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.

What Premera Blue Cross's policy requires for chronic wound care

Cited policy: BCBS Medical Policy: Bioengineered Skin and Soft Tissue Substitutes (BCBSA Ref. )

Patterned on CMS LCD L35041: dehydrated human amnion-chorion membrane (dHACM, EpiFix Q4186) for DFU or VLU >=4 weeks failed standard care, ABI >=0.65, no untreated osteomyelitis or active deep infection, <50% area reduction with conventional therapy. Up to 8-10 applications per episode with documented progress. Vascular workup required before initiation.

How Premera Blue Cross denies chronic wound care — and how to counter it

Where Premera Blue Cross pushes back: 1) Use cheaper CTP first (Apligraf / Dermagraft); 2) Insufficient evidence vs SOC; 3) >5 applications excessive; 4) Provider not specialty-credentialed.

Counter-arguments that hold up: Cite Zelen Int Wound J 2013;10(5):502-507 (DFU N=25 healing 92% dHACM vs 8% standard care, p<0.001 — fastest published DFU healing rate) + Zelen Int Wound J 2015;12(6):724-732 (head-to-head dHACM vs Apligraf vs SOC; dHACM superior at 4 + 6 wk closure) + Serena Vasc Endovasc Surg 2014 (VLU). HCPCS Q4186 reimbursed under standard ASP+6% — formulary tier preference cannot override medical necessity. CMS LCD L35041 does not mandate failure of one CTP before another; physician selects based on wound characteristics, depth, exudate, and prior history.

What Premera Blue Cross typically denies for chronic wound care

Across Premera Blue Cross's commercial and Medicare books, denials cluster around a small number of patterns. For chronic wound care, expect:

• WA-specific mental health parity violations
• Step therapy via Express Scripts
• Out-of-network reductions
• Specialty drug prior auth

Treatments most often denied in this category

These are the chronic wound care treatments most often flagged for prior auth, step therapy, or medical necessity review:

• HBOT
• NPWT (wound vac)
• Apligraf
• Dermagraft
• EpiFix (dHACM)
• Grafix

How to submit the appeal to Premera Blue Cross

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Premera Blue Cross cited in the denial.
3. File the appeal through Premera Blue Cross's portal (members: https://www.premera.com ; providers: https://www.premera.com/wa/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In WA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Premera Blue Cross's prior-authorization criteria by drug: Premera Blue Cross PA criteria on ApprovalHelp.